Zhongshan Hospital Fudan University
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT04495296 | |
| A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China | cardiovascular disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT03736226 | |
| Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Not yet recruiting | Phase 3 | 2026-09-21 | NCT07830433 | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 3 | 2026-08-27 | NCT07730489 | |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, gastric cancer, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 | 2026-08-13 | NCT07066657 | |
| A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Recruiting | Phase 2 | 2026-06-10 | NCT06986785 | |
| Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 2 | 2026-03-13 | NCT07198386 | |
| Evaluate the Safety and Clinical Activity of HH2853 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, T-cell non-Hodgkin lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-01-30 | NCT04390737 | |
| A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy | Primary Membranous Nephropathy | Active, not recruiting | Phase 2 | 2025-11-20 | NCT06642909 | |
| A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer | Advanced Biliary Tract Cancer | Recruiting | Phase 2 | 2025-07-02 | NCT06978114 | |
| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors | hepatocellular carcinoma | Recruiting | Phase 1 | 2025-01-08 | NCT06764836 | |
| Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II | Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Not yet recruiting | Not stated | 2023-03-10 | NCT05764356 |